Compare Cassava Sciences Inc (FLNA) vs Vanguard Total World Stock Index Fund ETF (VT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Vanguard Total World Stock Index Fund ETF — how do they compare? Cassava Sciences Inc trades at $1.06 (market cap $53.14M), while Vanguard Total World Stock Index Fund ETF trades at $156.14. The key difference: Vanguard Total World Stock Index Fund ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | VT | |
|---|---|---|
Market Cap | $53.14M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $4.64 | $159.35 |
52-Week Low | $1.09 | $128.41 |
Enterprise Value | -$33.43M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
The Vanguard Total World Stock ETF (VT) trades at $156.24, down 0.34% on the day. Technical indicators show a bullish trend from moving averages, with neutral oscillators suggesting consolidation near key support at $155. The fund provides global equity diversification with over 10,000 holdings across developed and emerging markets, maintaining a low expense ratio of 0.06%.
VT offers comprehensive global exposure but faces competition from lower-cost alternatives. The fund's broad diversification reduces single-country risk, though its performance remains tied to global economic conditions. A dividend of $0.56 per share is scheduled for payment on June 23, 2026, providing income alongside growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Vanguard Total World Stock Index Fund ETF
VT is a foundational, low-cost ETF that seeks to track the FTSE Global All Cap Index, providing exposure to nearly 10,000 stocks across developed and emerging markets worldwide, including the United States. It serves as a single-ticker solution for total global equity diversification, capturing approximately 98% of the world's investable market capitalization.
Read more on VT →
